Andrew Parsonson/X
Dec 10, 2024, 05:50
Andrew Parsonson: DB-1311 shows encouraging activity and safety in multiple tumours
Andrew Parsonson, Medical Oncologist, Macquarie University Clinical Associates, shared a post on X:
“DB-1311 (B7-H3 Target ADC with TOP1i payload) uORR 56% in SCLC and encouraging activity and safety in multiple tumours (NSCLC, CRPC, HCC, HNSCC, CC, Melanoma) Dose expansion recruitment ongoing.”
Christina Teng, Medical Oncologist at Scientia Clinical Research Australia, shared this post on X, adding:
“This compound is going places!
Charlotte Lemech still recruiting Scientia Clinical Research Australia. Hope ESMOASIA2024 is a blast! Looking forward to Australian Rare Cancer Portal. GC, BTC, sarcoma, GBM results to come. Also great to see Australian oncologists coming on board and others in Australia.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 8, 2025, 17:18
Jan 8, 2025, 17:18
Jan 8, 2025, 17:14
Jan 8, 2025, 16:56
Jan 8, 2025, 15:44
Jan 8, 2025, 15:35
Jan 8, 2025, 15:31